Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
|
|
AVEO PHARMACEUTICALS, INC. (AVEO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/30/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 01/24/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/24/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/24/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/19/2023 |
4
| BATE KENNETH (Director) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 375 shares
@ $15, valued at
$5.6k
Disposed/sold 1,250 options to buy
@ $25.9, valued at
$32.4k
Disposed/sold 1,250 options to buy
@ $15.7, valued at
$19.6k
Disposed/sold 2,515 options to buy
@ $16.1, valued at
$40.5k
Disposed/sold 2,000 options to buy
@ $20, valued at
$40k
Disposed/sold 6,402 options to buy
@ $9.2, valued at
$58.9k
Disposed/sold 7,785 options to buy
@ $7, valued at
$54.5k
Disposed/sold 4,000 options to buy
@ $22.7, valued at
$90.8k
Disposed/sold 4,000 options to buy
@ $7.6, valued at
$30.4k
Disposed/sold 4,000 options to buy
@ $7.52, valued at
$30.1k
Disposed/sold 12,500 options to buy
@ $7.27, valued at
$90.9k
|
|
| 01/19/2023 |
4
| EVNIN ANTHONY B (Director) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 41,841 shares
@ $15, valued at
$627.6k
Disposed/sold 1,250 options to buy
@ $25.9, valued at
$32.4k
Disposed/sold 1,250 options to buy
@ $15.7, valued at
$19.6k
Disposed/sold 2,515 options to buy
@ $16.1, valued at
$40.5k
Disposed/sold 2,000 options to buy
@ $20, valued at
$40k
Disposed/sold 6,402 options to buy
@ $9.2, valued at
$58.9k
Disposed/sold 7,785 options to buy
@ $7, valued at
$54.5k
Disposed/sold 4,000 options to buy
@ $22.7, valued at
$90.8k
Disposed/sold 4,000 options to buy
@ $7.6, valued at
$30.4k
Disposed/sold 4,000 options to buy
@ $7.52, valued at
$30.1k
Disposed/sold 12,500 options to buy
@ $7.27, valued at
$90.9k
|
|
| 01/19/2023 |
4
| Ledell Jebediah (COO) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 170,000 options to buy
@ $5.92, valued at
$1M
Disposed/sold 27,702 options to buy
@ $3.67, valued at
$101.7k
|
|
| 01/19/2023 |
4
| Ferraresso Michael (Chief Commercial Officer) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 16,345 shares
@ $15, valued at
$245.2k
Disposed/sold 20,000 options to buy
@ $28.3, valued at
$566k
Disposed/sold 3,749 options to buy
@ $30.8, valued at
$115.5k
Disposed/sold 35,064 options to buy
@ $6.2, valued at
$217.4k
Disposed/sold 42,499 options to buy
@ $5.6, valued at
$238k
Disposed/sold 100,000 options to buy
@ $9.12, valued at
$912k
Disposed/sold 220,000 options to buy
@ $3.67, valued at
$807.4k
|
|
| 01/19/2023 |
4
| Epperly Corinne (Director) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 10,000 options to buy
@ $6.31, valued at
$63.1k
Disposed/sold 15,000 options to buy
@ $6.46, valued at
$96.9k
Disposed/sold 22,500 options to buy
@ $4.27, valued at
$96.1k
|
|
| 01/19/2023 |
4
| Cullen Kevin Joseph (Director) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 25,000 options to buy
@ $6.3, valued at
$157.5k
Disposed/sold 22,500 options to buy
@ $4.27, valued at
$96.1k
|
|
| 01/19/2023 |
4
| Spring Scarlett (Director) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 10,000 options to buy
@ $6.6, valued at
$66k
Disposed/sold 4,000 options to buy
@ $7.52, valued at
$30.1k
Disposed/sold 12,500 options to buy
@ $7.27, valued at
$90.9k
Disposed/sold 22,500 options to buy
@ $4.27, valued at
$96.1k
|
|
| 01/19/2023 |
4
| Mayes, Gregory T. (Director) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 10,000 options to buy
@ $6.1, valued at
$61k
Disposed/sold 4,000 options to buy
@ $7.52, valued at
$30.1k
Disposed/sold 12,500 options to buy
@ $7.27, valued at
$90.9k
Disposed/sold 22,500 options to buy
@ $4.27, valued at
$96.1k
|
|
| 01/19/2023 |
4
| BAILEY MICHAEL P (President & CEO) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 333,167 shares
@ $15, valued at
$5M
Disposed/sold 3,249 options to buy
@ $77.2, valued at
$250.8k
Disposed/sold 11,999 options to buy
@ $25.1, valued at
$301.2k
Disposed/sold 7,499 options to buy
@ $17.7, valued at
$132.7k
Disposed/sold 90,000 options to buy
@ $8.4, valued at
$756k
Disposed/sold 46,000 options to buy
@ $10.8, valued at
$496.8k
Disposed/sold 75,366 options to buy
@ $6, valued at
$452.2k
Disposed/sold 99,999 options to buy
@ $30.8, valued at
$3.1M
Disposed/sold 16,750 options to buy
@ $15.7, valued at
$263k
Disposed/sold 93,500 options to buy
@ $6.2, valued at
$579.7k
Disposed/sold 35,302 options to buy
@ $5.6, valued at
$197.7k
|
|
| 01/19/2023 |
4
| Lucera Erick (CFO) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 50,000 options to buy
@ $6.7, valued at
$335k
Disposed/sold 100,000 options to buy
@ $9.12, valued at
$912k
Disposed/sold 218,800 options to buy
@ $3.67, valued at
$803k
|
|
| 01/19/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 01/19/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/19/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/19/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/19/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/19/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/19/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/19/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/19/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/19/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/19/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/19/2023 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa... |
| 01/18/2023 |
8-K
| Quarterly results |
| 01/05/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 01/03/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 12/23/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 12/22/2022 |
4
| BAILEY MICHAEL P (President & CEO) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.|
Txns:
| Exercised 26,499 options to buy
@ $6.2, valued at
$164.3k
Exercised 85,722 options to buy
@ $5.6, valued at
$480k
Exercised 164,525 options to buy
@ $3.67, valued at
$603.8k
|
|
| 12/20/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 12/02/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 12/02/2022 |
8-K
| Quarterly results |
|
|
|